A detailed history of Ronald Blue Trust, Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 113 shares of BPMC stock, worth $12,715. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113
Previous 135 16.3%
Holding current value
$12,715
Previous $11,000 18.18%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025

SELL
$82.48 - $101.39 $1,814 - $2,230
-22 Reduced 16.3%
113 $9,000
Q4 2024

Jan 22, 2025

BUY
$82.48 - $101.39 $5,773 - $7,097
70 Added 107.69%
135 $11,000
Q3 2024

Oct 17, 2024

BUY
$84.1 - $120.5 $252 - $361
3 Added 4.84%
65 $6,000
Q2 2024

Jul 18, 2024

BUY
$85.18 - $108.78 $5,281 - $6,744
62 New
62 $6,000
Q4 2023

Jan 18, 2024

BUY
$43.96 - $92.84 $395 - $835
9 New
9 $0
Q2 2022

Aug 09, 2022

BUY
$45.23 - $70.15 $226 - $350
5 New
5 $0

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.72B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.